Global Anti-Anemic Drug Market 2031 Forecast & Trends

The Global Anti-Anemic Drug Market is projected to reach USD 24.7 billion by 2031, growing from USD 17.9 billion in 2026. This represents a robust Compound Annual Growth Rate (CAGR) of 6.7% over the forecast period, driven by persistent global anemia prevalence and an aging population.

The primary drivers include the persistently high global prevalence of anemia, particularly among women of reproductive age and children, and the increasing global burden of chronic diseases. Conditions like Chronic Kidney Disease (CKD) and cancer significantly boost demand for therapeutics, further amplified by the rising geriatric population who are more susceptible to anemia.

The market is witnessing a fundamental shift with the successful regulatory expansion of novel oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHIs), particularly in major Asian markets like China. These new orally administered therapies are expanding treatment access to large patient populations, such as those with non-dialysis-dependent CKD, thereby increasing overall market size and patient adherence due to an improved administration route.

While anemia remains a critical concern globally, particularly in low- and middle-income regions, major Asian markets such as China are specifically highlighted for the successful regulatory expansion of oral HIF-PHIs. This indicates a significant regional shift in therapeutic access and market growth for advanced anti-anemic treatments.

Stringent government regulations, exemplified by policies like Germany's AMNOG, are intensifying pricing pressure on both originator and biosimilar anti-anemic drugs. This environment directly shifts demand toward more cost-effective generic and biosimilar alternatives, compelling major pharmaceutical manufacturers to recalibrate their commercial and research strategies.

The future outlook indicates continued evolution beyond traditional iron and vitamin supplements and ESAs, with new orally administered therapies entering key regional formularies. This shift necessitates that pharmaceutical manufacturers recalibrate strategies to capture both the mass-market nutritional segment and specialized therapeutic areas linked to chronic disease management, ensuring sustained market expansion.